Story
Braveheart Bio Prices IPO at $18 Per Share, Raising $382.5 Million

Braveheart Bio, Inc., a clinical-stage biopharmaceutical company, announced it has priced its initial public offering at $18.00 per share. The offering is expected to raise gross proceeds of $382.5 million to advance its pipeline of cardiovascular disease treatments.
Offering Details
According to a company press release, Braveheart Bio is offering 21,250,000 shares of its common stock. The stated gross proceeds do not account for underwriting discounts, commissions, and other related expenses.
Underwriters have also been granted a 30-day option to purchase up to an additional 3,187,500 shares at the IPO price. The company's shares are expected to begin trading on the Nasdaq Global Market on August 6, 2026, under the ticker symbol "BRVE". The offering is anticipated to close on August 7, 2026, subject to customary closing conditions.
Use of Proceeds and Pipeline
AdThe capital raised is expected to support the development of the San Francisco-based company's lead product candidate, BHB-1893. Braveheart Bio is focused on developing treatments for cardiovascular diseases.
BHB-1893 is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick.
Underwriting Syndicate
A consortium of investment banks is managing the deal. Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint book-running managers for the offering.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.